Genocea Biosciences Announces Pricing of Initial Public Offering at $12 per Share

Genocea Biosciences (NASDAQ: GNCA) today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts. In addition, Genocea has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on February 5, 2014 under the ticker symbol “GNCA." The offering is expected to close on February 10, 2014, subject to customary closing conditions. Citigroup and Cowen and Company are acting as joint book-running managers for the offering. Stifel is acting as lead manager and Needham & Company, LLC is acting as co-manager. A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on February 4, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy and there shall not be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a prospectus, copies of which may be obtained from Citigroup c/o Broadridge Financial Solutions, 1155 Long Island Ave., Edgewood, NY 11717, by calling (800) 831-9146, or by emailing batprospectusdept@citi.com, or Cowen and Company c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, by calling (631) 274-2806, or by fax (631) 254-7140. About Genocea Biosciences, Inc. Genocea is harnessing the power of T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods. Genocea is able to identify protective T cell antigens in humans exposed to a pathogen using ATLAS™, its proprietary technology platform, potentially enabling vaccines against pathogens for which vaccine solutions do not exist or are sub-optimal. Genocea's pipeline of novel T cell vaccines includes GEN-003 for HSV-2 therapy, GEN-004, and earlier-stage programs in chlamydia, HSV-2 prophylaxis and malaria.